Double dose of deals as Celgene buys Avila, Amgen nabs Micromet

Celgene ($CELG) snapped up Avila Therapeutics and its early-stage Btk inhibitor in a "grand slam" buyout that could hit $925 million with milestone payments. And not to be left out of the day's M&A fervor, Amgen ($AMGN) picked up Micromet ($MITI) for $1.2 billion, citing its "better way to kill tumor cells" as part of the attraction. Article | Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.